1. Home
  2. ACU vs HURA Comparison

ACU vs HURA Comparison

Compare ACU & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACU
  • HURA
  • Stock Information
  • Founded
  • ACU 1867
  • HURA 2009
  • Country
  • ACU United States
  • HURA United States
  • Employees
  • ACU N/A
  • HURA N/A
  • Industry
  • ACU Industrial Machinery/Components
  • HURA
  • Sector
  • ACU Consumer Discretionary
  • HURA
  • Exchange
  • ACU Nasdaq
  • HURA Nasdaq
  • Market Cap
  • ACU 145.9M
  • HURA 126.1M
  • IPO Year
  • ACU N/A
  • HURA N/A
  • Fundamental
  • Price
  • ACU $41.30
  • HURA $2.50
  • Analyst Decision
  • ACU
  • HURA Strong Buy
  • Analyst Count
  • ACU 0
  • HURA 2
  • Target Price
  • ACU N/A
  • HURA $11.50
  • AVG Volume (30 Days)
  • ACU 11.0K
  • HURA 278.8K
  • Earning Date
  • ACU 10-17-2025
  • HURA 11-13-2025
  • Dividend Yield
  • ACU 1.56%
  • HURA N/A
  • EPS Growth
  • ACU N/A
  • HURA N/A
  • EPS
  • ACU 2.55
  • HURA N/A
  • Revenue
  • ACU $194,061,991.00
  • HURA N/A
  • Revenue This Year
  • ACU $4.69
  • HURA N/A
  • Revenue Next Year
  • ACU $6.15
  • HURA N/A
  • P/E Ratio
  • ACU $16.12
  • HURA N/A
  • Revenue Growth
  • ACU 0.70
  • HURA N/A
  • 52 Week Low
  • ACU $34.35
  • HURA $1.80
  • 52 Week High
  • ACU $45.42
  • HURA $8.40
  • Technical
  • Relative Strength Index (RSI)
  • ACU 46.35
  • HURA 44.51
  • Support Level
  • ACU $41.70
  • HURA $2.28
  • Resistance Level
  • ACU $43.71
  • HURA $2.65
  • Average True Range (ATR)
  • ACU 1.55
  • HURA 0.17
  • MACD
  • ACU -0.05
  • HURA -0.04
  • Stochastic Oscillator
  • ACU 19.88
  • HURA 23.91

About ACU Acme United Corporation.

Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: